Medicare has begun reimbursing Lucid Diagnostics $1,938 per test for its EsoGuard Esophageal DNA Test under the Clinical Laboratory Fee Schedule. The company also closed a $15 million private placement to support commercialization.
A study of 60,449 lab results found that using broader screening thresholds doubled detection rates of primary aldosteronism compared to Endocrine Society guidelines, according to research in Hypertension.
Biodesix, in collaboration with Bio-Rad and Thermo Fisher Scientific, is advancing decentralized tumor-informed and tumor-naïve MRD assays designed for clinical labs, with validation underway at Memorial Sloan Kettering Cancer Center.
The Signals LabGistics tool translates standard operating procedures into scientific workflows and supports GxP compliance across laboratory environments.
Quest Diagnostics and Waters Corp will expand at-home HPV screening nationwide in 2027, offering extended genotyping via the FDA-cleared Onclarity Self-Collection Kit through clinical, health plan, and consumer channels.
